Onconetix (ONCO) EBT Margin (2024 - 2026)
Onconetix (ONCO) posted quarterly EBT Margin of 6426.99% for Q4 2025, up 240551.0% year-over-year from N/an in Q4 2024, and up 322.18% quarter-over-quarter from 2892.7% in Q3 2025.
Onconetix (ONCO) EBT Margin (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported EBT Margin for 2 consecutive years, with 6426.99% the latest figure, recorded in Q4 2025.
- In Q4 2025, EBT Margin rose 240551.0% year-over-year to 6426.99%; the TTM figure through Mar 2026 stood at 1946.51% (down 204805.0% YoY), while the FY2025 annual figure was 2338.64%, down 230901.0% from the prior year.
- EBT Margin rose to 6426.99% in Q4 2025 per ONCO's latest filing, from 2892.7% in the prior quarter.
- Across five years, EBT Margin topped out at 6426.99% in Q4 2025 and bottomed at 8545.88% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Onconetix | 1.42 Mn | -4.52 Mn | 4,303.00 | -16,748.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,748.27% |
| Mar 31, 2026 | -19,643.36% |
| Dec 31, 2025 | 6,426.99% |
| Sep 30, 2025 | -2,892.70% |
| Jun 30, 2025 | -2,227.77% |
| Mar 31, 2025 | -8,545.89% |
| Dec 31, 2024 | 4,021.48% |
| Sep 30, 2024 | -970.95% |
| Jun 30, 2024 | -2,022.55% |
| Mar 31, 2024 | -1,604.74% |